Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: In vitro results and clinical responses

Cancer Immunology, Immunotherapy

Volumn 58, Issue 10, 2009, Pages 1587-1597

  Zhou, Jun ^a   Weng, Desheng ^a   Zhou, Fangjian ^a   Pan, Ke ^a   Song, Haifeng ^a   Wang, Qijing ^a   Wang, Huan ^a   Wang, Hui ^a   Li, Yongqiang ^a   Huang, Lixi ^a   Zhang, Huakun ^a   Huang, Wei ^a   Xia, Jianchuan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Cell fusion; Dendritic cell; Immunotherapy; Renal cell carcinoma; T cell activation

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; HLA A2 ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CELL FUSION; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; IN VITRO STUDY; KIDNEY CARCINOMA; KIDNEY TUMOR; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MIDDLE AGED; T LYMPHOCYTE; VACCINATION;

ADULT; AGED; CANCER VACCINES; CARCINOMA, RENAL CELL; CELL FUSION; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; YOUNG ADULT;

EID: 68549094461     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0668-9     Document Type: Article

References (38)

1. Rohrmann K, Staehler M, Haseke N, Bachmann A, Stief CG, Siebels M (2005) Immunotherapy in metastatic renal cell carcinoma. World J Urol 23:196-201 (Pubitemid 41136042)
2. Schrader AJ, Varga Z, Hegele A, Pfoertner S, Olbert P, Hofmann R (2006) Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J Cancer Res Clin Oncol 132:137-149 (Pubitemid 43015774)
3. Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80:1198-1220
4. Bukowski RM (2000) Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol 27:204-212
5. Fisher RI, Rosenberg SA, Fyfe G (2000) Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6:S55-S57
6. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with longterm follow-up. J Clin Oncol 11:1368-1375 (Pubitemid 23199143)
7. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18:2972-2980 (Pubitemid 30644121)
8. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338:1272-1278 (Pubitemid 28216581)
9. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 9:271-296
10. Romani N, Gruner S, Brang D, Kämpgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180:83-93 (Pubitemid 24181058)
11. Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony stimulating factor plus interleukin 4 and down regulated by tumor necrosis factor alpha. J Exp Med 179:1109-1118
12. Alexander M, Salgaller ML, Celis E, Sette A, Barnes WA, Rosenberg SA, Steller MA (1996) Generation of tumor-specific cytotoxic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 BA46 epitope. Am J Obstet Gynecol 175:1586-1593 (Pubitemid 27021032)
13. Kim CJ, Prevette T, Cormier J, Overwijk W, Roden M, Restifo NP, Rosenberg SA, Marincola FM (1997) Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocyte in vitro. J Immunother 20:276-286 (Pubitemid 28011539)
14. McArthur JG, Mulligan RC (1998) Induction of protective antitumor immunity by gene-modified dendritic cells. J Immunother 21:41-47 (Pubitemid 28044835)
15. Paglia P, Chiodoni C, Rodolfo M, Colombo MP (1996) Murine dendritic cells loaded in vitro with soluable protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317-322 (Pubitemid 26028774)
16. Philip R, Brunette E, Ashton J, Alters S, Gadea J, Sorich M, Yau J, O'Donoghue G, Lebkowski J, Okarma T, Philip M (1998) Tansgene expression in dendritic cells to induce antigen-specific cytotoxic T cells in healthy donors. Cancer Gene Ther 5:236-246 (Pubitemid 128640010)
17. Sonderbye L, Feng S, Yacoubian S, Buehler H, Ahsan N, Mulligan R, Langhoff E (1998) In vivo and in vitro modulation of immune stimulatory capacity of primary dendritic cells by adenovirus-mediated gene transduction. Exp Clin Immunogenet 15:100-111 (Pubitemid 28334063)
18. Young JW, Inaba K (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 183:7-11 (Pubitemid 26028740)
19. Zivotgel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation and T helper cell I-associated cytokines. J Exp Med 183:87-97 (Pubitemid 26028748)
20. Koido S, Nikrui N, Ohana M, Xia J, Tanaka Y, Liu C, Durfee JK, Lerner A, Gong J (2005) Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecol Oncol 99:462-471 (Pubitemid 41502861)
21. Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, Qanadli S, Steinmann B, Burnier M, Palecek T, Bultas J, Hayoz D (2006) Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol 26:839-844 (Pubitemid 43732160)
22. Liu J, Matsuo H, Xu Q, Chen W, Wang J, Maruo T (2007) Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro. Hum Reprod 22:1253-1259 (Pubitemid 47062792)
23. Thiery J, Dorothée G, Haddada H, Echchakir H, Richon C, Stancou R, Vergnon I, Benard J, Mami-Chouaib F, Chouaib S (2003) Potentiation of a tumor cell susceptibility to autologous CTL killing by restoration of wild-type p53 function. J Immunol 170:5919-5926 (Pubitemid 36682571)
24. Zhang XY, Li WG, Wu YJ, Zheng TZ, Li W, Qu SY, Liu NF (2005) Proanthocyanidin from grape seeds potentiates anti-tumor activity of doxorubicin via immunomodulatory mechanism. Int Immunopharmacol 5:1247-1257 (Pubitemid 40725718)
25. Fujiwara T, Oda K, Yokota S, Takatsuki A, Ikehara Y (1988) Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum. J Biol Chem 263:18545-18552 (Pubitemid 19005133)
26. Fong L, Engleman EG (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245-273 (Pubitemid 30365381)
27. Zou W (2005) Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 5:263-274
28. Chen D, Xia J, Tanaka Y, Chen H, Koido S, Wernet O, Mukherjee P, Gendler SJ, Kufe D, Gong J (2003) Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 109:300-307 (Pubitemid 36683622)
29. Gong J, Chen D, Kashiwaba M, Kufe D (1997) Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3:558-561 (Pubitemid 27198656)
30. Gong J, Chen D, Kashiwaba M, Li Y, Chen L, Takeuchi H, Qu H, Rowse GJ, Gendler SJ, Kufe D (1998) Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 95:6279-6283 (Pubitemid 28249003)
31. Koido S, Tanaka Y, Chen D, Kufe D, Gong J (2002) The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J Immunol 168:2111-2117 (Pubitemid 34171809)
32. Xia J, Tanaka Y, Koido S, Liu C, Mukherjee P, Gendler SJ, Gong J (2003) Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol 170:1980-1986 (Pubitemid 36197418)
33. Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, Cannistra S, Avigan D, Kufe D (2000) Fusions of human ovarianc arcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 165:1705-1711 (Pubitemid 30604610)
34. Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, Watanabe M, Yanaga K, Fujise K, Tajiri H, Gong J, Toda G (2005) Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin Cancer Res 11:7891-7900 (Pubitemid 41611636)
35. Koido S, Hara E, Torii A, Homma S, Toyama Y, Kawahara H, Ogawa M, Watanabe M, Yanaga K, Fujise K, Gong J, Toda G (2005) Induction of antigen specific CD4 and CD8 mediated T cell responses by fusions of autologous dendritic cells and metastatic colorectal cancer cells. Int J Cancer 117:587-595 (Pubitemid 41504546)
36. Koido S, Tanaka Y, Tajiri H, Gong J (2007) Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells. Vaccine 25:2610-2619 (Pubitemid 46400930)
37. Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM (2007) Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 30:749-761 (Pubitemid 47480758)
38. Märten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, Von Ruecker A, Eis-Hübinger AM, Müller S, Schwaner I, Lohmann U, Heylmann G, Sauerbruch T, Schmidt-Wolf IG (2003) Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 14:483-494 (Pubitemid 36403540)